Simpler Grants.gov #PAR-25-074

Cancer Assay Validation for Clinical Studies – NIH/NCI Research Opportunity

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is inviting applications for the validation of molecular, cellular, and imaging markers and assays relevant to cancer clinical studies. - Government Buyer: - National Institutes of Health (NIH), National Cancer Institute (NCI) - Products/Services Requested: - Analytical and clinical validation of assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance - Includes validation of pharmacodynamic and toxicity markers - Project Structure: - UH2 phase: Analytical validation (up to 2 years) - UH3 phase: Clinical validation using biospecimens from clinical studies (up to 3 years) - Unique Requirements: - Multidisciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists is required - No specific OEMs or vendors are named; opportunity is for investigator-initiated research - Open to educational institutions, nonprofits, government agencies, and tribal organizations - No specific part numbers, products, or OEMs are identified, as the focus is on research and assay development

Description

The National Cancer Institute (NCI) invites applications to support the validation of molecular, cellular, and imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance. This funding opportunity supports both analytical and clinical validation of assays for use in cancer treatment, control, or prevention trials. The UH2 phase supports analytical validation within 2 years, and the UH3 phase supports clinical validation for up to 3 years using well-annotated biospecimens. Projects require multidisciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists.

View original listing